Lorazepam Tablets, USP, 0.5mg, Unit Dose, 100 tablets per carton (10 x 10 blister packs), Rx only...
FDA Drug Recall #D-0226-2025 — Class II — January 21, 2025
Recall Summary
| Recall Number | D-0226-2025 |
| Classification | Class II — Moderate risk |
| Date Initiated | January 21, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories |
| Location | La Vergne, TN |
| Product Type | Drugs |
| Quantity | 82,281 cartons |
Product Description
Lorazepam Tablets, USP, 0.5mg, Unit Dose, 100 tablets per carton (10 x 10 blister packs), Rx only, The drug product contained in this package is from NDC # 69315-904 Leading Pharma, LLC., Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 26268 USA, NDC: 0904-6007-61
Reason for Recall
Failed impurities/degradation specifications and Sub-potent Drug: Out-of-specification results were obtained during routine stability testing for Assay and Impurities.
Distribution Pattern
Nationwide U.S. and Puerto rico
Lot / Code Information
Lot #s: N01424, N01425, Exp 03/31/2025; N01659, N01660, Exp 08/31/2025; N01668, 09/2025; N01679, N01704, N01745, Exp 10/31/2025; N01856, Exp 02/28/2026; N01973, Exp 05/31/2026; N02079, Exp 08/31/2026.
Other Recalls from The Harvard Drug Group LLC dba Major ...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0011-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0013-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0010-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0012-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
| D-0009-2026 | Class II | Major ChlorproMAZINE Hydrochloride Tablets, USP... | Sep 12, 2025 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.